Navigation Links
K-V Pharmaceutical Company Announces Filing of Fiscal Year 2010 Annual Report on Form 10-K With the Securities and Exchange Commission
Date:12/27/2010

forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995 (the "PSLRA") and that may be based on or include assumptions concerning the operations, future results and prospects of the Company. Such statements may be identified by the use of words like "plan," "expect," "aim," "believe," "project," "anticipate," "commit," "intend," "estimate," "will," "should," "could," "potential" and other expressions that indicate future events and trends.

All statements that address expectations or projections about the future, including without limitation, statements about product development, product launches, regulatory approvals, governmental and regulatory actions and proceedings, market position, acquisitions, sale of assets, revenues, expenditures, resumption of manufacturing and distribution of products and the impact of the recall and suspension of shipments on revenues, and other financial results, are forward-looking statements.

All forward-looking statements are based on current expectations and are subject to risk and uncertainties. In connection with the PSLRA's "safe harbor" provisions, the Company provides the following cautionary statements identifying important economic, competitive, political, regulatory and technological factors, among others, that could cause actual results or events to differ materially from those set forth or implied by the forward-looking statements and related assumptions.

Such factors include (but are not limited to) the following:

(1)  the ability to continue as a going concern;

(2)  the terms of our recently executed secured loan agreement with U.S. Healthcare I, L.L.C. and U.S. Healthcare II, L.L.C. (together, the "Lenders"), as more fully described in Item 1— "Business—(b) Significant Recent Developments—Financing" in the Company's Annual Report on Form 10-K for the year ended March 31, 2010 (the "Form 10-K"), could
'/>"/>

SOURCE K-V Pharmaceutical Company
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
2. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
5. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
6. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
7. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
8. Par Pharmaceutical Begins Shipment of Additional Dosage Strength of Generic TOPROL-XL(R)
9. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
10. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
11. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... 2014 Valeant Pharmaceuticals International, Inc. (NYSE: ... the company,s Bridgewater, New Jersey ... and Drug Administration (FDA) relating to an inspection in ... Sculptra Aesthetic injectable, which was divested to Galderma S.A. ... of Valeant,s contract manufacturers (rather than Valeant,s own internal ...
(Date:9/30/2014)... 2014 The Eastern European medical device industry ... as well as new medical-device manufacturers are constantly trying ... at ways to reduce the cost incurred for placing ... of the effective means to achieve this target. This ... Eastern European and provides profiles of key distributors in ...
(Date:9/30/2014)...   Decision Resources Group finds that through ... kidney disease non-dialysis (CKD-ND) patients are not highly ... addition, one-year persistency is similar between Amgen,s Aranesp ... findings from the report entitled Treatment ... Agents in Late Stage Chronic Kidney Disease and ...
Breaking Medicine Technology:Valeant Pharmaceuticals' Bridgewater Location Receives Warning Letter From FDA 2Medical Technologies Distributor Profiles in Eastern Europe 2Medical Technologies Distributor Profiles in Eastern Europe 3Persistency is Low for Late-Stage Anemic CKD Non-Dialysis Patients Treated with Erythropoiesis-Stimulating Agents 2Persistency is Low for Late-Stage Anemic CKD Non-Dialysis Patients Treated with Erythropoiesis-Stimulating Agents 3
... 2011 Cumberland Pharmaceuticals Inc. (Nasdaq: ... hospital acute care and gastroenterology markets, today announced that ... UBS Global Specialty Pharmaceuticals Conference in London on Wednesday, ... The presentation will be simultaneously webcast and can be ...
... 11, 2011 Doctors in Germany are among the ... States with the REVIVE™ SE, a new self-expanding blood ... clots and restore blood flow to the brain in ... Shurtleff, Inc., a global neuroscience and neurovascular company, received ...
Cached Medicine Technology:Doctors in Germany Among First to Use New Self-Expanding Clot Removal Device for Ischemic Stroke 2Doctors in Germany Among First to Use New Self-Expanding Clot Removal Device for Ischemic Stroke 3
(Date:9/30/2014)... 30, 2014 A new study ... studied the impact of stress on metabolism after eating a ... fries from a fast food restaurant, about 930 calories and ... for 20 minutes every hour for 7 hours, conducting the ... women who had experienced a stressful event in their lives ...
(Date:9/30/2014)... (PRWEB) September 30, 2014 Dynamic ... have hampered growth in the Bread Production industry ... caused consumers to moderate their consumption of a ... for premium varieties shrunk the market for white ... operators proactively responded by introducing more nutritious products ...
(Date:9/30/2014)... Integrated Medicine Alliance , Monmouth County’s ... medical specialty practice through a unique partnership with an ... located within the company’s Shrewsbury location and will be ... of American Heart Center, P.C., a highly regarded practice ... Integrated Medicine Alliance patients top notch cardiovascular care without ...
(Date:9/30/2014)... (FQHCs) granted new patient appointments to Medicaid beneficiaries ... primary care practices (non-FQHCs), in addition to charging ... new 10-state University of Pennsylvania study published this ... data from a previous "secret shopper" study conducted ... FQHCs community health clinics that receive federal ...
(Date:9/30/2014)... 30, 2014 Research by UC Irvine immunologists reveals ... light on a vital process that determines how the ... online version of Nature Immunology , neurology professor ... Institute for Immunology colleagues describe a critical mechanism underlying ... the bloodstream. , A T cell is a type ...
Breaking Medicine News(10 mins):Health News:NutriGold Urges Every Woman To Read a Recent Study About Diet and Stress 2Health News:NutriGold Urges Every Woman To Read a Recent Study About Diet and Stress 3Health News:Bread Production in the US Industry Market Research Report from IBISWorld Has Been Updated 2Health News:Bread Production in the US Industry Market Research Report from IBISWorld Has Been Updated 3Health News:Integrated Medicine Alliance Announces New Cardiology Practice 2Health News:Medicaid and Uninsured patients obtain new patient appointments most easily at FQHCs 2Health News:UCI study uncovers important process for immune system development 2
... April 27 Estill Medical Technologies, Inc., the industry ... announces the expansion of its Thermal Angel sales and ... mortality by quickly controlling core body temperature and infection ... administration. In emergency medicine, the golden hour refers to ...
... Members to Help Raise Obesity on the Nation,s Public ... health associations and obesity experts joined the S ... P revent (STOP) Obesity Alliance today as the organization ... grappling with the high costs of weight-related health conditions ...
... illnesses in which the immune system creates autoantibodies to ... non-profit Autoimmunity Research Foundation (ARF) explain that the antibodies ... human genes and gene products by hidden bacteria. , ... bacteria capable of causing human disease, But DNA discoveries ...
... Pharmaceuticals, a division of Wyeth (NYSE: ... has granted marketing authorization for CONBRIZA(TM) (bazedoxifene), a ... of postmenopausal osteoporosis in women at increased risk ... risk treatment guidelines and assessment tool for calculating ...
... Study shows those who respond to lapatinib survive longer, , , ... be used to treat aggressive inflammatory breast cancer, suggest the ... cancer accounts for up to 6 percent of all invasive ... to the researchers. Symptoms include rapid onset of swelling, ...
... to mirror Mandela,s values NEW YORK, April 27 46664 ... the world to support the creation of an official ... Mr. Mandela,s birthday. This celebration of Nelson Mandela,s life will ... recognize their individual power to make an imprint and help ...
Cached Medicine News:Health News:Thermal Angel Supports Infection Control During the Golden Hour 2Health News:As Health Reform Takes Shape, Leading Medical and Public Health Organizations Join Effort to Keep Obesity Front and Center 2Health News:As Health Reform Takes Shape, Leading Medical and Public Health Organizations Join Effort to Keep Obesity Front and Center 3Health News:As Health Reform Takes Shape, Leading Medical and Public Health Organizations Join Effort to Keep Obesity Front and Center 4Health News:'Autoantibodies' may be created in response to bacterial DNA 2Health News:Wyeth's CONBRIZA Approved in the European Union for Treatment of Postmenopausal Osteoporosis in Women at Increased Risk of Fracture 2Health News:Wyeth's CONBRIZA Approved in the European Union for Treatment of Postmenopausal Osteoporosis in Women at Increased Risk of Fracture 3Health News:Wyeth's CONBRIZA Approved in the European Union for Treatment of Postmenopausal Osteoporosis in Women at Increased Risk of Fracture 4Health News:Drug May Help Against Inflammatory Breast Cancer 2Health News:46664 and the Nelson Mandela Foundation Call for Establishment of Global 'Mandela Day' 2Health News:46664 and the Nelson Mandela Foundation Call for Establishment of Global 'Mandela Day' 3Health News:46664 and the Nelson Mandela Foundation Call for Establishment of Global 'Mandela Day' 4Health News:46664 and the Nelson Mandela Foundation Call for Establishment of Global 'Mandela Day' 5
For universal arthroscopic meniscal repair/suture. Uses double-armed, single-throw sutures....
... Great Toe Implant (KGTI) system offers the ... the first MPJ. The implant system is ... motion. , ,The KGTI is the most ... joint (MPJ) on the market today. The ...
... Intraoperative Electrodes share similar characteristics ... main difference is that all ... numbered to assist you intraoperatively. ... designed for use with either ...
... full field digital mammography system signals ... in the world of mammography. This ... the latest advances in digital imaging ... to bring you the total solution ...
Medicine Products: